News articles about Bio-Rad Laboratories (NYSE:BIO) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bio-Rad Laboratories earned a news impact score of 0.12 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.8874913937362 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Bio-Rad Laboratories, Inc. Clas (NYSE:BIO) Sees Significantly Higher Trading Volume (bulhufas.com)
- Bio-Rad Laboratories, Inc. (BIO) Given Buy Rating at Jefferies Group LLC (footballhebdo.com)
- Bio-Rad Laboratories (NYSE:BIO) Receiving Somewhat Favorable News Coverage, Study Finds (elcumanes.com)
- Bbva Compass Bancshares Inc. Reduces Stake in Bio-Rad Laboratories, Inc. (BIO) (overnewsmagazine.com)
- In Vitro Diagnostics (IVD) Quality Control Market- Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Randox Laboratories (medgadget.com)
Shares of Bio-Rad Laboratories (NYSE BIO) opened at 227.31 on Friday. The firm has a 50-day moving average of $228.57 and a 200 day moving average of $210.72. Bio-Rad Laboratories has a 1-year low of $143.39 and a 1-year high of $239.91. The stock has a market cap of $6.73 billion, a price-to-earnings ratio of 241.31 and a beta of 0.91.
Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, May 4th. The medical research company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.14. The firm had revenue of $500.05 million for the quarter, compared to the consensus estimate of $477.76 million. Bio-Rad Laboratories had a net margin of 1.35% and a return on equity of 3.23%. The business’s revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.42 earnings per share. Equities research analysts forecast that Bio-Rad Laboratories will post $2.94 earnings per share for the current year.
Several equities analysts recently weighed in on the stock. TheStreet cut shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday. Zacks Investment Research cut shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $250.00 price target on shares of Bio-Rad Laboratories in a research report on Thursday, April 27th. Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price target for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. Finally, Wells Fargo & Co assumed coverage on shares of Bio-Rad Laboratories in a research report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $228.80.
COPYRIGHT VIOLATION NOTICE: “Bio-Rad Laboratories (NYSE:BIO) Getting Somewhat Favorable News Coverage, Report Finds” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://stocknewstimes.com/2017/08/06/bio-rad-laboratories-nysebio-getting-somewhat-favorable-news-coverage-report-finds.html.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
